Completed PHASE2 INTERVENTIONAL NCT00204633

Darbepoetin Alfa in Patients With Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)

Randomized Phase II-Trial to Determine the Impact of Darbepoetin Alfa on the Frequency of RBC Transfusions in Patients With Metastatic Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP Regimen)

Sponsor: University Hospital Tuebingen

Conditions Dysgerminoma

Interventions Darbepoetin alfa

Updated 6 times since 2017 Last updated: Feb 13, 2009 Started: Jul 31, 2003 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Dysgerminoma and is currently completed. University Hospital Tuebingen leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Tuebingen

Data source: University Hospital Tuebingen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tübingen, Germany